SUMMARY.-Eighty patients with advanced metastatic renal cancer have been treated with hormones, chiefly medroxyprogesterone acetate (Provera). This progestational compound is remarkably free from side-effects and can be given in high dosage for long periods without serious complications. Ninety per cent of cases had multiple metastases: in 76% more than one organ was involved and nearly 50% were seriously ill or " terminal ".
marked improvement in the radiological or clinical signs of tumour within 2 to 6 weeks of commencing treatment or changing to a different hormone. In two further cases improved general health was associated with stationary metastases for 20 months. A significant objective response occurred in 16% of the total series. A favourable response was seen more often in men (21%) than in women (8%). If deaths within 6 weeks are excluded the objective response rate in men is increased to 27%. Although the response of advanced renal cancer to hormonal treatment is usually incomplete and of brief duration, it is possible for such treatment to offer a " new lease of life " to a seriously ill patient, even in old age, for 2 to 3 years. BETWEEN 75% and 80% of patients treated for renal cell carcinoma will die within 10 years of their primary treatment, the majority with distant metastases. In a few of these cases the natural history of the disease will be unusual. For example, growth of metastases may be exceptionally slow or, following removal of a solitary lesion, the patient may live for a number of years without further recurrence. Very rarely spontaneous regression of pulmonary deposits may occur. For the vast majority of cases, however, the onset of clinical metastases heralds death within a year or two.
The treatment of advanced renal cancer with cytotoxic drugs has been disappointing. Woodruff et al. (1967) reviewed the literature on this subject, and of 243 collected cases treated with 33 different non-hormonal agents only 10% showed signs of objective improvement: in most instances this was slight or of brief duration. Talley et al. (1969) have published their personal experience with various cytotoxic drugs against metastatic hypernephroma. Of 57 patients treated with 15 different non-hormonal compounds, chiefly alkylating agents, antimetabolites and vinblastine, objective improvement was seen in only two cases (3.50 %). Apart from these poor results, the agents employed are highly toxic and have a relatively small margin of safety.
* Based on a pa.per read at the Upjohn Symposium on " Provera in Treatment of Some
Malignancies ", The Royal Society of Medicine, October 27, 1970.
PROVERA TREATMENT OF METASTATIC RENAL CANCER
In previous publications we have drawn attention to clinical, pathological and experimental evidence in support of the concept of a hormonal background to carcinoma of the kidney, and to the possibility of achieving worthwhile palliation in a small proportion of very advanced cases by the administration of gonadal hormones, chiefly progestins (Bloom et al., 1963a (Bloom et al., 1963b Bloom and Wallace, 1964; Bloom, 1964 Bloom, , 1967 . Such agents appear to be not only more successful in controlling the disease than cytotoxic drugs, but are also remarkably free from serious side-effects following prolonged administration in large doses.
A transplantable renal adenocarcinoma of the golden hamster, induced by prolonged oestrogen administration (Matthews et al., 1947; Kirkman, 1959; Horning, 1956 ), has been employed as an experimental model with which to try and find hormonal agents which may be of value in the treatment of advanced renal cancer in man (Bloom et al., 1963a .
Primary tumour induction in the hamster by oestrogen can be inhibited by the simultaneous administration of testosterone or progesterone (Kirkman, 1959; Horning, 1956) . Provera combined with cortisone, but not alone, markedly reduced the growth rate of " independent " tumour transplants (Bloom et al., 1963a) . Actual tumour regression was achieved by orchiectomy and this action was nullified by the administration of oestradiol (Bloom et al., 1963b) . For this reason the effect of anti-oestrogens.was investigated and the first of these studied, U-llOOA (Upjohn Ltd.), a diphenyldihydronaphthaline derivative, had a marked inhibitory effect on the transplantable tumour . Other agents, including those with known anti-oestrogenic properties, are under investigation in our laboratories at the present time.
Caution is necessary when trying to extrapolate from observations in laboratory animals to clinical practice, but because the principal actions of hormonal agents are fundamentally alike in most species, it is tempting to apply knowledge derived from endocrine-dependent tumours in animals to possibly analogous tumours in man. Although the kidney is not generally regarded as a member of the endocrine system, a direct link between hormones and human renal cancer exists in the rare but well-recognised association of renal cell carcinoma with polycythaemia and with hypercalcoemia due to the " ectopic " secretion of erythropoietin and parathormone, respectively, by the tumour.
The male predominance found in renal cortical carcinoma series and in cases of spontaneous regression of this tumour, the effect of sex hormones on the normal kidney in experimental animals, and the induction and inhibition of the hamster renal tumour by such agents, encouraged us in 1959 to embark on a clinical trial of gonadal hormones, chiefly the progestin, provera, in patients with advanced renal cancer (Bloom, 1964) .
PATIENTS AND METHODS
Between 1959 and 1969 80 patients with incurable renal adenocarcinoma have been treated with hormonal agents. Only cases with clear evidence of advancing disease for whom no other treatment, except by cytotoxic drugs, was feasible were accepted for hormone therapy. In this category no case was refused treatment, no matter how near death they appeared to be. Thus, 20 very ill patients died within 6 weeks of commencing hormone treatment (25% of the total).
The series consisted of 54 men and 26 women. A nephrectomy had been carried out in 67 patients and histological confirmation of the diagnosis of renal 20 (Table I) .
Thirty-eight cases (47%) were seriously ill or considered to be " terminal" when hormone therapy was instituted. In 19 cases (24%), the liver was enlarged, in eight as far as the umbilicus. Seven patients had cerebral metastases. Skeletal deposits were present in 23 (29%) cases, and pulmonary or mediastinal lesions in 57 (71%). A laparotomy in seven patients revealed that proper removal of the primary tumour was impossible (Table I) . Treatment in all cases was initiated with progestins-Provera in 79 cases and Delalutin in one case. Provera or medroxypyrogesterone acetate (6a-methyl, 17a-acetoxy-progesterone) is a powerful progestational agent synthesized in the laboratories of Upjohn Ltd (Babock et al., 1958) which is devoid of oestrogenic and androgenic properties. It may be given orally or as a suspension intramuscularly. Prolonged administration to patients even in high doses (300-400 mg. daily) appears to be virtually free from serious toxic effects. In the present series the oral preparation of Provera was used 100 mg. t.i.d. Delalutin or Primolut Depot (Schering) (hydroxyprogesterone caproate) was given in a dose of 250 mg. i.m. thrice weekly. 
RESULTS
Of the 80 cases 78 have been followed until death; one foreign patient remains untraced and one case is still alive. A significant degree of subjective improvement was experienced by 44 patients (55%) following the administration of one or more hormone preparations. Attention will be given only to cases with PROVERA TREATMENT OF METASTATIC RENAL CANCER 253 objective signs of tumour regression or where the tumour remained stationary for more than 1 year. In this category ten cases thought to show some response have been mentioned but excluded from the final consideration because the change was of a very limited nature, lasted for 1 month or less, or was not confirmed by the present author.
Eleven cases (14%) remain in which undeniable improvement in the radiological or clinical signs of tumour occurred within a short time of commencing treatment or changing to a different hormone and lasted for 2-35 months (Tables II and  III) . There were two additional cases in whom marked improvement in general condition was associated with stationary tumour for 20 and 21 months respectively (Table IV) . Histological confirmation of the diagnosis was obtained in all 13 cases, and in five of the 11 dead cases an autopsy was performed. The overall significant objective response rate is 16% (13 of 80 cases). If the 20 seriously ill patients who died within 6 weeks of starting hormone therapy are excluded on the grounds of insufficient time for a chemotherapeutic effect, a practice endorsed by several authors, the response rate is 22% (Table VI) . Case B.S., female aged 58 (Bloom, 1967) General condition very poor, massive tumour in solitary kidney and hard irregular liver to umbilicus. Nephrectomy for tuberculosis 32 years previously. Recent excision of thyroid mass which showed metastatic clear cell adenocarcinoma. Nephrotomogram revealed small cap of functioning renal tissue atop a large renal tumour. Oral Provera 300 mg. daily started. After 10 days improved general condition, increased appetite, weight gain, more physical activity with less fatigue and renal mass smaller: hepatomegaly unchanged. Discharged from hospital after 6 weeks with renal tumour approximately one-third of its original size, but liver unchanged. General improvement and response of primary tumour maintained for 2 months after which there was deterioration and increasing hepatomegaly. No response to testosterone. Death 3 months after commencing hormone therapy. Autopsy: large renal tumour showing extensive areas of necrosis and calcification. Histology: residual clear cell adenocarcinoma and extensive areas of anaplastic tumour with marked pleomorphism and hyperchromatism.
Re'sume.-Rapid partial regression of massive primary tumour. Unchanged metastatic liver. Was the partial response limited to the areas of more differentiated tumour?
Total Selective Regression Case G.D., male aged 64 (Bloom, 1964) Presented with renal tumour and solitary pulmonary shadow. Pre-operative irradiation for primary tumour during which time pulmonary deposit increased. Nephrectomy carried out. Two months later chest X-ray showed numerous bilateral lung lesions. Oral Provera, 300 mg. daily, started. Five weeks later pulmonary deposits reduced in size and number, and after 2 months all but two lesions had disappeared. These remained stationary for Case W.D., male aged 59 (Bloom, 1964) Huge . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . look better within a week or 10 days. In six cases evidence of tumour regression was seen within 2 weeks. From this experience it seems that if a hormone preparation fails to improve a patient with renal cancer it is unnecessary to delay the trial of an alternative preparation beyond 6 to 8 weeks. It is interesting to note that progestin-induced histological changes in cases of endometrial cancer were observed within only 4 weeks in 75% of responding cases: in the remaining 25% such changes were delayed for 8-12 weeks (Sherman, 1966) . On the other hand, experience elsewhere with renal cancer has indicated that signs of improvement may not appear until 2 months after starting hormone therapy (Samuels et al., 1968; Paine et al., 1970) . Talley and his colleagues (1969) had to wait as long as 5 and 8 months before observing regression in their two cases. Our current policy is not to interrupt the initial hormone treatment so long as the patient's general condition is satisfactory and the recurrent or metastatic disease remains stationary.
DIJRATION OF LIFE IN HORMONE-TREATED CASES
In the present series the average duration of life from onset of hormone treatment in 78 of the 80 cases was 7-2 months. Of the remaining two cases one is still alive at 20 months and the other is untraced. This average figure is comparable to that reported by Royce and Tormey (1955) for non-hormone treated cases presenting pre-operatively with metastases (6-7 months), and to that for patients with local tumour extension outside the kidney at operation (5.7 months). The average survival for 67 non-responding hormone-treated cases in the present series was 5 2 months, whereas that for 11 patients (13 less one untraced and one still alive) showing a well-marked objective response to hormone therapy was substantially longer-19.6 months. Compared with advanced cases not treated with hormones this is a conservative figure, since the duration of life in the present series had been measured from the onset of hormone therapy which in many patients was introduced some time after the appearance of recurrent tumour. It appears that an objective response of renal carcinoma to hormone therapy is accompanied by prolongation of life, a conclusion also reached by Samuels et al. (1968) .
FACTORS RELATED TO HORMONE-RESPONSE

Sex
Reference has already been made to the influence of sex on the development of renal tumours in hamsters and on the incidence of carcinoma of the human kidney (Bloom, 1964) . In the present series marked objective improvement following hormone therapy was seen more often in men (11 of 54 cases, 20%) than in women (two of 26 cases, 8%). Furthermore, the response in each of the two female cases was of a very limited nature. The best results in the present series, including the total disappearance of large metastatic or recurrent tumours, have been confined to men. On the other hand, Samuels et al. (1968) refer to a woman aged 56 with complete regression of an abdominal recurrence during treatment with Provera and in whom the response was still maintained at 30 months.
If the 20 extremely ill patients who died within 6 weeks of commencing hormone therapy are excluded, the proportion of cases showing a marked response to this treatment is increased to 27% for men, compared with 10% for women (Table   VI) . It is well known that tumour growth rate in men with prostatic cancer may be increased by the administration of testosterone, and in pre-menopausal women with breast cancer by oestrogen.
Apparent tumour acceleration during hormone treatment of renal cancer occurred in five cases in the present series. In two of these, however, the increase in tumour size was probably related to an inflammatory reaction, perhaps associated with acute necrosis, since the swelling subsided spontaneously within a few hours or days whilst the patient continued on the same hormone. In the remaining three cases the changes were progressive and associated with deterioration in general health: this was so rapid in one case as to demand emergency admission to hospital within 48 hours of commencing hormone treatment. Acceleration of tumour growth with serious consequences during hormone therapy occurred in three of our 80 cases, an incidence of 4%. The hormone in two patients was Provera and in the third, testosterone. Clinical improvement in all three patients occurred with a change in hormone preparation. In one patient skeletal and intrathoracic metastases increased rapidly during Provera treatment: manifestations of intracranial metastases appeared and the patient's general condition quickly deteriorated. When testosterone was substituted for the progestin, the patient improved quite dramatically, returning rapidly to good health without evidence of active disease for 3 years (Case D.W.) (Bloom and Wallace, 1964) . Although tumour stimulation by hormones was not observed in experiments with the strain of transplanted hamster renal carcinoma used in our laboratories (Bloom et al., 1963a) , an increase in tumour growth rate was reported by Kirkman (1959) when testosterone was administered to stilboestrol-treated animals bearing the transplanted " oestrogen-dependent" strain of tumour.
The possible stimulation of renal cancer during hormone treatment must be borne in mind, and patients should be seen at short intervals in the early stages of such treatment. For this reason we have waited for clear evidence of advancing disease before embarking on endocrine therapy. Renal cancer metastases may occasionally remain latent for a time, or progress only very slowly, and in such patients no treatment at all may be preferable to a regime which may disturb a satisfactory tumour-host relationship. This concept is particularly important if hormone administration is ever considered in a prophylactic role as part of the curative treatment of primary renal carcinoma. 21
REPORTS IN THE LITERATURE
Six reports from other centres concerning the treatment of advanced renal cancer with hormones are shown in Table VII . Apart from the groups reported by Jenkin (1967) and by Talley et al. (1969) the overall picture is that of one in five or six cases responding to this treatment. An objective response was seen in 16% of the total of 173 collected cases, including those in the present series (Table VII) . 
SPONTANEOUS REGRESSION OF RENAL CARCINOMA
True spontaneous partial or complete regression of cancer is a well-recognised but rare event. Renal cell carcinoma is one of the principal tumours in which this phenomenon has been observed, and the obvious question now is whether the regression of metastases in our hormone-treated cases is the result of treatment or due to an unrelated spontaneous event.
From a study of the world literature between 1900 and 1965 and from cases obtained by personal enquiry Everson and Cole (1966) were only able to collect 176 cases in which they considered there to be adequate evidence of spontaneous regression of malignant disease. Thirty-one cases had carcinoma of the kidney. Two of these patients, however, had received hormones (testosterone and prednisone) and one, thalidamide. In two further cases the evidence of regression was based entirely on pathological changes in the primary tumour, one being atrophic and the other showing necrosis, cyst formation and calcification.
To the 26 cases of clinical regression of untreated renal cancer reported by Everson and Cole (1966) up to the end of 1965 we can add two further cases reported during this period and six others published since then, making a total of 34 examples in the literature up to the end of 1969 (Table VIII) . Although unreported cases have undoubtedly been seen, the incidence of spontaneous regression in renal cancer seems to be extraordinarily rare.
In a series of 98 cases of renal cancer presenting with metastases and with a possible follow-up of 12 months reported by Middleton (1967) none showed signs of spontaneous regression with or without nephrectomy: 91 cases were dead by 1 year and all 98 by 2 years. No examples of spontaneous regression were observed by Riches (1963) in 130 cases of renal carcinoma, by Arner and Von Schreeb (1966) in 232 cases, and by Rafla (1970) (1966) 
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Gonick and Jackiw (1964) 1 Andrews (1965) . 1 Mims et al. (1966) . spontaneous regression of skeletal metastases following nephrectomy is reported by Mims et al. (1966) in their series of 97 cases of advanced renal cancer of which 57 presented with distant metastases. In a personal series of almost 200 patients with renal cancer referred for radiotherapy or hormone treatment over the past 10 years, I have seen two cases in whom spontaneous disappearance of pulmonary metastases occurred. In one unimpressive case, a woman of 70, brief spontaneous regression of pulmonary deposits occurred over 3 months and during this time mediastinal nodes increased and vaginal metastases appeared (Bloom, 1967) . Events in the second case were far more striking.
Case F.B., male aged 55 Nephrectomy for renal carcinoma in presence of bilateral pulmonary metastases. At operation renal tumour involved peritoneum. In keeping with a " wait and see " policy Provera treatment not undertaken at this stage. Two months after operation metastases in left lung smaller; by 5 months all metastases showed signs of regression, and by 7 months all but one had disappeared. Lungs became clear 10 months after nephrectomy. Patient remains in excellent health with clear chest more than 2 years after operation (Bloom and Riddle 1971 , not yet published).
In all but two of 36 cases of spontaneous regression (34 in Table VIII plus two mentioned here) improvement was confined to pulmonary metastases (Table IX) . Only one example of spontaneous regression of skeletal metastases has been found in the literature (Mims et al., 1966) . The other case showing regression of extrapulmonary deposits, although accepted by Everson and Cole (1966) , seems rather dubious; residual or recurrent renal carcinoma tissue was said to have been passed per rectum (Klimpel, 1957) .
In the present series of hormone-treated patients clinical evidence of wellmarked tumour regression was observed in the lungs (five cases), in large abdominal tumours (six cases), in the kidney itself (one case) and in the skeleton (one case) (Table IX) . In a further case not included in this table skeletal deposits remained unchanged for 21 months (case A.D.). It would seem that striking and prolonged regression of widespread metastases involving the brain, chest and skeleton, such as occurred in one of our patients (case D.W.), and the virtual disappearance of a huge abdominal tumour in another (case J.A.D.) , have yet to be reported as a spontaneous event in patients with advanced renal cell carcinoma.
The occurrence of spontaneous regression of renal carcinoma, although a rare event, naturally calls for caution in the interpretation of the results of hormone therapy, and emphasises the importance of waiting for clear signs of progressive 261 disease before embarking on such treatment. In view of the rarity of spontaneous improvement of metastatic renal carcinoma it would appear that definite regression in 11 cases, continued tumour standstill for 20 months in two others, and minor or doubtful regressive changes in ten others, in a consecutive series of 80 cases receiving hormone therapy, is more likely to be due to the treatment than to a natural event. This concept is strongly supported by the short interval between commencing or changing hormone treatment and observing clinical or radiological signs of improvement. Furthermore, there are now reports of similar experience from other centres (Melander et al., 1967; Samuels et al., 1968; Talley et al., 1969; Paine et al., 1970) .
Although the phenomenon of spontaneous regression of renal cancer has been purposely stressed here, the fact remains that once the presence of visceral or skeletal metastases is established, the disease, in the great majority of untreated patients, advances and causes death within a year or two.
DISCUSSION AND CONCLUSIONS
The hormonal control of advanced renal cancer, as well as tumours arising in well-established target organs, such as the breast and endometrium, is temporary and largely unpredictable as to frequency and duration. Until a lead can be obtained from further clinical experience or from organ tissue culture and perhaps biochemical studies, the choice of hormone preparation and dose for a particular patient with renal cancer must remain largely empirical. Once it is clear that the disease is advancing and that neither radiotherapy nor surgery are feasible we have started treatment with Provera, 100 mg. thrice daily by mouth. If there is no response to this preparation within 8 weeks, or a shorter time if the patient is rapidly deteriorating, a change has been made to testosterone propionate, 100 mg. intramuscularly on 5 days per week, later reduced to on 3 days per week. If this failed we sometimes tried stilboestrol, 15 to 30 mg. daily, or prednisone using initial doses of 40 mg. daily. Although Samuels et al. (1968) remarked on the absence of objective responses in cases of renal cancer treated with Proveraby mouth, tumour regression with this progestin can undoubtedly follow oral as well as parenteral treatment.
Because a combination of cortisone and Provera produced a more striking inhibitory effect on the transplantable hamster renal tumour than cortisone alone (Bloom et al., 1963a) , both hormones were tried together in a few patients who failed to respond to Provera but without success. Significant tumour regression 262 PROVERA TREATMENT OF METASTATIC RENAL CANCER was not observed with corticosteroids or with stilboestrol. Brief subjective improvement was produced occasionally by prednisone.
Although one patient in this series had a remarkable remission lasting 3 years with testosterone (case D.W.), progestins appear to be generally more effective than androgens in the treatment of advanced renal cancer. Only one of 15 cases treated initially with testosterone by Jenkin (1967) showed an objective response.
In two cases of renal carcinoma reported by Talley and his colleagues (1969) objective responses were not apparent until 5 and 8 months respectively had elapsed from onset of hormone therapy. It may therefore be advisable to continue with the initial hormone preparation for longer than the 6 to 8 weeks which has been our policy in the present series. Perhaps the treatment should not be interfered with as long as the patient's general condition remains satisfactory and the metastases stationary.
It must be emphasised that hormone administration is not the treatment of choice for patients with solitary metastases. Such cases are first considered for surgical ablation (e.g. lung or brain deposit) or, if this is not feasible, for radiotherapy (e.g. spinal or multiple brain deposits). Local irradiation offers a quick and more certain relief of symptoms in metastatic renal cancer than does systemic treatment with hormones or cytotoxic agents.
Prolonged administration of Provera in oral doses of 100 mg. three times daily is well tolerated and does not appear to be associated with serious side-effects. Liver and thyroid function tests and glucose tolerance carried out at intervals in some of our long-term cases remained normal, and there was no fall in plasma cortisol levels nor in 17-hydroxyketo-steroid excretion. Nevertheless, it is advisable to continue to watch for endocrine and perhaps hepatic complications. Macdonald (1970) has reported a reduced adrenal response to metyrapone stimulation tests during treatment with Provera. Stoll et al. (1966) have found raised serum transaminase levels together with histological evidence of hepatocellular damage in patients taking the progestin, lynoestrenol, a derivative of 19, nortestosterone.
We have recently observed degenerative changes in the wall of the ascending aorta with vascular rupture in hamsters treated with large doses of megesterol or melengesterol acetate, compounds with progestational and anti-oestrogenic activity and structurally closely related to Provera (Cobb et al., 1971) . Although this complication has fortunately not been observed in any of our patients treated with large doses of Provera, in view of possible changes in the aorta and also the risk of thrombo-embolic disorders related to the progestational component of contraceptive pills (Inman et al., 1970) , special attention should be given to the cardiovascular system in advanced cancer cases treated with large doses of progestins that come to autopsy.
Enhanced tumour activity together with marked general deterioration has been seen in two cases in the present series receiving Provera and one testosterone. Bergsjo (1965) to screen various hormonal preparations against tumour fragments from patients with carcinoma of the kidney by measuring the inhibition of tritiated thymidine incorporated into DNA, and the degree of degeneration seen in ordinary histological sections. In this way it is hoped to find the most effective hormonal agent with which to start treatment in a particular patient. Some of the technical difficultics have now been overcome, but there remains the problem of obtaining a viable piece of tissue with which to attempt in vitro growth from a tumour which so often contains necrotic areas.
To date there have been too few tissue culture studies from our cases treated for metastatic renal cell carcinoma with hormonal agents to permit corrclation between in vitro and clinical response. More work needs to be done in this interesting field, especially since hormonal agents, at least in vitro, appear to act directly on renal tumour cells whilst sparing normal kidney tissue-a potentially most desirable state of affairs for the chemical treatment of cancer.
The inhibitory effect of hormones on renal carcinoma may be a direct one at the cellular level and not mediated through the pituitary. This view is supported by tissue culture studies (Tchao et al., 1968) , and also by the absence of signs of pituitary inhibition (based on thyroid function tests, plasma cortisol levels and 17-hydroxycorticosteroid excretion in the urine) in our patients treated with Provera. On the other hand, this compound may possess some pituitary inhibitory effect as shown by gonadal atrophy in animals (Ericsson and Dutt, 1965) , a reduced adrenal response to the metyrapone test (Macdonald, 1970) and gonadal suppression in patients with sexual precocity (Kupperman and Epstein, 1962) .
Spontaneous regression does not appear to be the explanation for the wellmarked objective response seen in 13 of 80 hormone-treated cases of advanced renal cancer in the present series, nor in those reported in the literature. If, indeed, a natural process and not treatment was responsible for the changes observed, then its incidence in renal cell cancer must be far greater than at present generally appreciated. On the contrary, the story of spontaneous regression in renal cancer favours rather than detracts from the concept of hormone-dependency in this disease. The process of spontaneous improvement itself in patients with renal cancer appears to be sex-related, 80% of such cases being males.
On the basis of the present material and the reports in the literature there seems little doubt that a limited number of renal cell carcinomas can be influenced by hormone therapy, and that this treatment may occasionally offer a new lease of life for a limited period of time to seriously ill patients, even at age 80. Approximately one in five or six patients appear to derive some benefit from hormone treatment. In a few other cases the degree of regression is not significant or clinical improvement is only transitory. Our experience with oral Provera indicates that striking improvement may occur within 4 weeks of starting treatment and, with continued high doses, last for up to 2 years.
Treatment of cancer with progestational agents is an attractive proposition since, unlike cytotoxic agents, they are exceptionally free from side-effects. Patients receiving large doses of Provera, daily over many months or even several years appear to remain in good health.
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